Investors Capital Advisory Services’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Investors Capital Advisory Services’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-5,178	Closed	-$261K	–	727
2015 Q4	$261K	Sell	5,178 -806	-13%	-$39.8K	0.05%	486
2015 Q3	$273K	Hold	5,984	–	–	0.05%	475
2015 Q2	$349K	Buy	5,984 +225	+4%	+$12.9K	0.06%	421
2015 Q1	$317K	Buy	5,759 +782	+16%	+$42.3K	0.06%	443
2014 Q4	$249K	Buy	+4,977	New	+$244K	0.05%	509

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TAM

Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

HBT

Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Investors Capital Advisory Services's PBE Position: Q1 2016 in Review

Investors Capital Advisory Services sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2016, closing a stake of 5,178 shares — an estimated $261K sold.

Investors Capital Advisory Services first reported a position in PBE in Q4 2014 and held it in 5 quarters. The position peaked at $349K in Q2 2015. 71 funds tracked by Wall St. Rank hold PBE as of Q1 2016.

Investors Capital Advisory Services reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2016 after selling out during the quarter.
Investors Capital Advisory Services sold 5,178 Invesco Biotechnology & Genome ETF shares in Q1 2016, an estimated $261K.
Investors Capital Advisory Services first reported a position in Invesco Biotechnology & Genome ETF in Q4 2014 and held it in 5 quarters.
Investors Capital Advisory Services's Invesco Biotechnology & Genome ETF position peaked at $349K in Q2 2015.
71 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2016.

Based on Investors Capital Advisory Services's 13F filing for Q1 2016, filed 9 May 2016.